Galderma Laboratories LP announces that it has received US Food and Drug Administration (FDA) approval for the use of Restylane Lyft, a hyaluronic acid (HA) dermal filler, with a small blunt tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21.

A small blunt tip cannula is a thin, flexible tube with a small opening on the side that provides an effective means for delivering fillers.

This approval is the second cannula indication for the Restylane family of dermal fillers. Restylane Silk for lip augmentation and Restylane Lyft for the midface are the only HA fillers on the market that are FDA-approved for use via cannula.

Read the full press release at